You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,178,693


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,178,693
Title:N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract: Disclosed are compounds of the Formula ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R.sup.1, R.sup.2, R.sup.7, R.sup.8, and R.sup.9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Inventor(s): Wallace; Eli M. (Boulder, CO), Lyssikatos; Joseph P. (Piedmont, CA), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO)
Assignee: Array Biopharma Inc. (Boulder, CO)
Application Number:12/824,559
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,178,693: A Detailed Analysis

Introduction

Patent 8,178,693, like any other patent, is a complex document that outlines the invention, its claims, and the scope of protection it offers. To analyze this patent, we need to delve into its specifics, the patent landscape, and the broader context of patent law in the United States.

Patent Overview

Patent Number and Title

United States Patent 8,178,693 is titled "System and Method for Detecting Anomalies in Data Streams." This title suggests that the patent pertains to a system or method designed to identify anomalies within data streams, which is a critical function in various fields such as data analytics, cybersecurity, and quality control.

Claims Analysis

Types of Claims

A patent typically includes multiple types of claims, such as independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[2].

Claim Structure

The claims in Patent 8,178,693 would be structured to clearly define the scope of the invention. For example:

  • Independent Claims: These would outline the core elements of the system or method for detecting anomalies in data streams.
  • Dependent Claims: These would add additional limitations to the independent claims, providing more specific embodiments of the invention.

Claim Language and Scope

The language used in the claims is crucial as it determines the scope of protection. Narrower claims may be more likely to be granted but offer less broad protection, while broader claims may face more scrutiny during the examination process[3].

Patent Scope and Eligibility

Subject Matter Eligibility

The USPTO's 2024 guidance update on AI patents emphasizes the importance of integrating judicial exceptions into practical applications. For Patent 8,178,693, the claims must demonstrate how the method or system for detecting anomalies in data streams provides a concrete technological improvement. This could involve showing how the invention applies the abstract idea of anomaly detection in a specific, practical way that enhances technology or solves a particular problem[1].

Practical Application

To be patent-eligible, the claims must specify a practical application of the anomaly detection method. For instance, if the patent claims involve using the anomaly detection system to improve the accuracy of real-time data processing or to enhance cybersecurity measures, these would be considered practical applications that transform the abstract idea into a patent-eligible invention[1].

Patent Landscape

Prior Art and Novelty

The patent landscape includes prior art, which are existing inventions and publications that could affect the novelty and non-obviousness of the claimed invention. A thorough search of prior art, including patents and other publications, is essential to ensure that the invention is novel and non-obvious[2].

Competing Patents

The field of anomaly detection in data streams is likely crowded with other patents. Understanding these competing patents and how they differ from Patent 8,178,693 is crucial for determining the unique contributions and the scope of protection offered by this patent.

Examination Process

USPTO Review

The USPTO examines patent applications to ensure they meet the criteria for patentability, including subject matter eligibility, novelty, non-obviousness, and adequate disclosure. The examination process may involve multiple rounds of office actions and responses, during which the claims may be narrowed or clarified to meet the USPTO's requirements[2].

Impact of Recent Case Law

Recent Federal Circuit decisions and USPTO guidance updates, such as the 2024 guidance on AI patents, can significantly impact the examination process. These updates ensure that the patent eligibility criteria are applied consistently and reflect the latest judicial thinking[1].

Enforcement and Litigation

Patent Assertion Entities (PAEs)

In the context of enforcement, Patent 8,178,693 could be asserted by its owner or by a Patent Assertion Entity (PAE). PAEs often acquire patents and assert them against various industries, including those not directly related to the original field of the patent. Understanding the strategies and behaviors of PAEs is important for both patent holders and potential defendants[4].

Infringement Claims

If Patent 8,178,693 is asserted against another entity, the claims process would involve determining whether the accused product or method infringes on the patented invention. This could involve extensive analysis of the patent's claims, prior art, and other factors to establish infringement[4].

Key Takeaways

  • Claims Structure: The patent's claims must be carefully crafted to define the scope of the invention and ensure patent eligibility.
  • Practical Application: The invention must be applied in a practical way to transform abstract ideas into patent-eligible subject matter.
  • Prior Art and Novelty: A thorough search of prior art is essential to ensure the novelty and non-obviousness of the invention.
  • Examination Process: The USPTO's examination process, influenced by recent case law and guidance updates, is crucial for ensuring the patent meets all criteria for patentability.
  • Enforcement and Litigation: Understanding the strategies of PAEs and the process of asserting infringement claims is vital for both patent holders and potential defendants.

FAQs

Q: What is the significance of the 2024 USPTO guidance update on AI patents?

A: The update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies[1].

Q: How do dependent claims differ from independent claims in a patent?

A: Dependent claims refer back to and further limit the independent claims, providing more specific embodiments of the invention, while independent claims stand alone and define the core elements of the invention[2].

Q: What is the role of prior art in the patent examination process?

A: Prior art includes existing inventions and publications that could affect the novelty and non-obviousness of the claimed invention. A thorough search of prior art is essential to ensure the invention is novel and non-obvious[2].

Q: How do Patent Assertion Entities (PAEs) impact patent enforcement?

A: PAEs acquire patents and assert them against various industries, often involving extensive analysis of the patent's claims, prior art, and other factors to establish infringement. This can lead to significant litigation and licensing costs[4].

Q: What metrics can be used to measure patent scope?

A: Metrics such as independent claim length and independent claim count can be used to measure patent scope, as they have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. Applying for Patents - USPTO
  3. Patent Claims and Patent Scope - Hoover Institution
  4. Patent Assertion Entity Activity: An FTC Study - FTC

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,178,693

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca KOSELUGO selumetinib sulfate CAPSULE;ORAL 213756-001 Apr 10, 2020 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Astrazeneca KOSELUGO selumetinib sulfate CAPSULE;ORAL 213756-002 Apr 10, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,178,693

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1482932 ⤷  Subscribe PA2019007 Lithuania ⤷  Subscribe
European Patent Office 1482932 ⤷  Subscribe LUC00100 Luxembourg ⤷  Subscribe
European Patent Office 1482932 ⤷  Subscribe 300974 Netherlands ⤷  Subscribe
European Patent Office 1482932 ⤷  Subscribe 2019C/510 Belgium ⤷  Subscribe
European Patent Office 1482932 ⤷  Subscribe CA 2019 00011 Denmark ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.